Status: Recruiting
A Study of TXN10128 in Subjects With Solid Tumors
This is a phase I clinical trial to primarily evaluate the safety, tolerability, and addtionally assess pharmacokinetics, pharmacodynamics, and antitumor activity of investigational product, TXN10128. The target subjects will be consisted of patients with locally advanced (unresectable) or metastatic soild tumors. This study includes a dose-escalation part and a dose-expansion part, and a TXN10128 monotherapy part and a TXN10128 + Irinotecan or Paclitaxel combination therapy part.
Participants needed: 96
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Txinno Bioscience Inc.Updated: Apr 24, 2025Locations: 6
Eligibility criteria
Male or female subjects ≥19 years of age at the time of informed consent. [+3]
Has leptomeningeal disease. [+3]